{"title":"西门子和Healthineers: IPO估值","authors":"Robert S. Harris, P. Holtz","doi":"10.2139/ssrn.3697552","DOIUrl":null,"url":null,"abstract":"This case covers the initial public offering (IPO) of the Siemens AG subsidiary Healthineers. The case offers the opportunity to discuss IPOs and to value the company. In contrast to \"Healthineers: A Strategic IPO\" (UVA-F-1881), which provides some base case valuation analysis, this version of the case is designed to be used when a primary teaching objective is to have students perform more of the analysis. The material is set in 2018, when CEO Joe Kaeser and the management board of Siemens planned an IPO of its Healthineers subsidiary to support the company's continued success and spur entrepreneurial independence. The IPO would position Healthineers to compete successfully in the global health care market, which was quite different from other sectors in which Siemens, a global technology conglomerate, operated. While Siemens would maintain a substantial equity interest, Healthineers would become a separate public company with increased flexibility and autonomy. In the immediate term, the management team was especially interested in what value financial markets would place on Healthineers once it was a public company. \n \nExcerpt \n \nUVA-F-1913 \n \nRev. Feb. 24, 2020 \n \nSiemens and Healthineers: Valuing the IPO \n \nBy early March 2018, CEO Joe Kaeser and the management board of Siemens AG (Siemens) had been focused on the progress of its Healthineers subsidiary for several years. Management planned an initial public offering (IPO) of Healthineers in mid-March to support the company's continued success and spur entrepreneurial independence. The IPO would position Healthineers to compete successfully in the global health care market, which was quite different from other sectors in which Siemens—a global technology conglomerate—operated (see Exhibit 1). Though Siemens would maintain a substantial equity interest, Healthineers would become a separate public company with increased flexibility and autonomy. \n \nBecause Siemens would be a long-term shareholder, Kaeser and the board had a keen interest in Healthineers's strategy and performance. Would the company continue to drive profitable growth in the short term? Tap into adjacent growth markets in the medium term? Be a market leader in health care? In the immediate term, the board was especially interested in what value financial markets would place on Healthineers once it was a public company. \n \nSiemens Healthineers AG \n \n. . .","PeriodicalId":121773,"journal":{"name":"Darden Case: Business Communications (Topic)","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Siemens and Healthineers: Valuing the IPO\",\"authors\":\"Robert S. Harris, P. Holtz\",\"doi\":\"10.2139/ssrn.3697552\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This case covers the initial public offering (IPO) of the Siemens AG subsidiary Healthineers. The case offers the opportunity to discuss IPOs and to value the company. In contrast to \\\"Healthineers: A Strategic IPO\\\" (UVA-F-1881), which provides some base case valuation analysis, this version of the case is designed to be used when a primary teaching objective is to have students perform more of the analysis. The material is set in 2018, when CEO Joe Kaeser and the management board of Siemens planned an IPO of its Healthineers subsidiary to support the company's continued success and spur entrepreneurial independence. The IPO would position Healthineers to compete successfully in the global health care market, which was quite different from other sectors in which Siemens, a global technology conglomerate, operated. While Siemens would maintain a substantial equity interest, Healthineers would become a separate public company with increased flexibility and autonomy. In the immediate term, the management team was especially interested in what value financial markets would place on Healthineers once it was a public company. \\n \\nExcerpt \\n \\nUVA-F-1913 \\n \\nRev. Feb. 24, 2020 \\n \\nSiemens and Healthineers: Valuing the IPO \\n \\nBy early March 2018, CEO Joe Kaeser and the management board of Siemens AG (Siemens) had been focused on the progress of its Healthineers subsidiary for several years. Management planned an initial public offering (IPO) of Healthineers in mid-March to support the company's continued success and spur entrepreneurial independence. The IPO would position Healthineers to compete successfully in the global health care market, which was quite different from other sectors in which Siemens—a global technology conglomerate—operated (see Exhibit 1). Though Siemens would maintain a substantial equity interest, Healthineers would become a separate public company with increased flexibility and autonomy. \\n \\nBecause Siemens would be a long-term shareholder, Kaeser and the board had a keen interest in Healthineers's strategy and performance. Would the company continue to drive profitable growth in the short term? Tap into adjacent growth markets in the medium term? Be a market leader in health care? In the immediate term, the board was especially interested in what value financial markets would place on Healthineers once it was a public company. \\n \\nSiemens Healthineers AG \\n \\n. . .\",\"PeriodicalId\":121773,\"journal\":{\"name\":\"Darden Case: Business Communications (Topic)\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Darden Case: Business Communications (Topic)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2139/ssrn.3697552\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Darden Case: Business Communications (Topic)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.3697552","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
本案例涉及西门子子公司Healthineers的首次公开募股(IPO)。这个案例提供了讨论ipo和评估公司价值的机会。“Healthineers: A Strategic IPO”(UVA-F-1881)提供了一些基本案例估值分析,与之不同的是,这一版本的案例设计用于主要教学目标是让学生进行更多分析的情况。故事的背景设定在2018年,当时西门子首席执行官乔·凯瑟尔和管理委员会计划将旗下子公司Healthineers上市,以支持该公司的持续成功,并刺激企业的独立性。此次IPO将使Healthineers在全球医疗保健市场上取得成功,这一市场与全球科技集团西门子(Siemens)经营的其他行业截然不同。尽管西门子将保留大量股权,但Healthineers将成为一家独立的上市公司,拥有更大的灵活性和自主权。在短期内,管理团队特别感兴趣的是,一旦Healthineers成为上市公司,金融市场会给它什么样的价值。截至2018年3月初,西门子公司(Siemens AG)首席执行官乔·凯瑟尔(Joe Kaeser)和管理委员会多年来一直关注其子公司Healthineers的进展。管理层计划在3月中旬对Healthineers进行首次公开募股(IPO),以支持公司的持续成功并刺激企业的独立性。首次公开募股将使Healthineers在全球医疗保健市场上成功竞争,这与西门子(一家全球科技集团)运营的其他行业截然不同(见表1)。尽管西门子将保留大量股权,但Healthineers将成为一家独立的上市公司,拥有更大的灵活性和自主权。由于西门子将成为长期股东,凯瑟尔和董事会对Healthineers的战略和业绩有着浓厚的兴趣。公司能否在短期内继续推动盈利增长?在中期打入邻近的成长型市场?成为医疗保健领域的市场领导者?在短期内,董事会特别感兴趣的是,一旦Healthineers成为上市公司,金融市场会给它什么样的价值。西门子医疗设备有限公司
This case covers the initial public offering (IPO) of the Siemens AG subsidiary Healthineers. The case offers the opportunity to discuss IPOs and to value the company. In contrast to "Healthineers: A Strategic IPO" (UVA-F-1881), which provides some base case valuation analysis, this version of the case is designed to be used when a primary teaching objective is to have students perform more of the analysis. The material is set in 2018, when CEO Joe Kaeser and the management board of Siemens planned an IPO of its Healthineers subsidiary to support the company's continued success and spur entrepreneurial independence. The IPO would position Healthineers to compete successfully in the global health care market, which was quite different from other sectors in which Siemens, a global technology conglomerate, operated. While Siemens would maintain a substantial equity interest, Healthineers would become a separate public company with increased flexibility and autonomy. In the immediate term, the management team was especially interested in what value financial markets would place on Healthineers once it was a public company.
Excerpt
UVA-F-1913
Rev. Feb. 24, 2020
Siemens and Healthineers: Valuing the IPO
By early March 2018, CEO Joe Kaeser and the management board of Siemens AG (Siemens) had been focused on the progress of its Healthineers subsidiary for several years. Management planned an initial public offering (IPO) of Healthineers in mid-March to support the company's continued success and spur entrepreneurial independence. The IPO would position Healthineers to compete successfully in the global health care market, which was quite different from other sectors in which Siemens—a global technology conglomerate—operated (see Exhibit 1). Though Siemens would maintain a substantial equity interest, Healthineers would become a separate public company with increased flexibility and autonomy.
Because Siemens would be a long-term shareholder, Kaeser and the board had a keen interest in Healthineers's strategy and performance. Would the company continue to drive profitable growth in the short term? Tap into adjacent growth markets in the medium term? Be a market leader in health care? In the immediate term, the board was especially interested in what value financial markets would place on Healthineers once it was a public company.
Siemens Healthineers AG
. . .